Literature DB >> 33987132

Gemfibrozil-Induced Polyuria.

Ashraf Oe Ahmed1, Edmond Okotcha2, Abdul-Hussein Saad2.   

Abstract

Gemfibrozil is a lipid-regulating agent used mainly to treat patients with hypertriglyceridaemia, especially those at risk for acute pancreatitis. Like any other pharmacological agent, gemfibrozil has known adverse effects, mainly gastrointestinal, such as cholelithiasis, gallstones, elevated transaminase, and other non-specific symptoms including dyspepsia, nausea and vomiting. Other reported adverse reactions are dizziness and vertigo, myopathy and rhabdomyolysis, angioedema, urticaria and rash. As far as we knew, gemfibrozil does not have urinary tract adverse reactions. In this report, we present a case of polyuria secondary to gemfibrozil with a score of 9 on the Naranjo scale, and a literature review. LEARNING POINTS: Gemfibrozil has known, mainly gastrointestinal, adverse effects.We aim to increase awareness of the urinary side effects of gemfibrozil so unnecessary investigations can be avoided. © EFIM 2021.

Entities:  

Keywords:  Gemfibrozil; anti-hyperlipidaemic; polyuria; urinary side effects

Year:  2021        PMID: 33987132      PMCID: PMC8112090          DOI: 10.12890/2021_002546

Source DB:  PubMed          Journal:  Eur J Case Rep Intern Med        ISSN: 2284-2594


  8 in total

1.  Acute renal failure secondary to interstitial acute nephritis and Fanconi syndrome for metamizole and gemfibrozil.

Authors:  Juan Antonio Martín-Navarro; Vladimir Petkov-Stoyanov; María José Gutiérrez-Sánchez; Luis Pedraza-Cezón
Journal:  Nefrologia       Date:  2015-08-05       Impact factor: 2.033

2.  Gemfibrozil, food and drug administration-approved lipid-lowering drug, increases longevity in mouse model of late infantile neuronal ceroid lipofuscinosis.

Authors:  Arunava Ghosh; Suresh Babu Rangasamy; Khushbu K Modi; Kalipada Pahan
Journal:  J Neurochem       Date:  2017-04-03       Impact factor: 5.372

Review 3.  Long-chain omega-3 fatty acids, fibrates and niacin as therapeutic options in the treatment of hypertriglyceridemia: a review of the literature.

Authors:  Matthew K Ito
Journal:  Atherosclerosis       Date:  2015-06-11       Impact factor: 5.162

4.  Gemfibrozil disrupts the metabolism of circulating lipids in bobwhite quails.

Authors:  Sophie Bussière-Côté; Teye Omlin; Eliana de Càssia Pinheiro; Jean-Michel Weber
Journal:  Comp Biochem Physiol C Toxicol Pharmacol       Date:  2015-09-30       Impact factor: 3.228

5.  Effect of gemfibrozil on cardiotoxicity induced by doxorubicin in male experimental rats.

Authors:  Habib Haybar; Mehdi Goudarzi; Saeed Mehrzadi; Azadeh Aminzadeh; Mohammad Javad Khodayar; Mojtaba Kalantar; Iman Fatemi
Journal:  Biomed Pharmacother       Date:  2018-11-06       Impact factor: 6.529

Review 6.  Dyslipidemia management in primary prevention of cardiovascular disease: Current guidelines and strategies.

Authors:  Aditya D Hendrani; Tolulope Adesiyun; Renato Quispe; Steven R Jones; Neil J Stone; Roger S Blumenthal; Seth S Martin
Journal:  World J Cardiol       Date:  2016-02-26

Review 7.  Intolerance to statins: mechanisms and management.

Authors:  Rafael Bitzur; Hofit Cohen; Yehuda Kamari; Dror Harats
Journal:  Diabetes Care       Date:  2013-08       Impact factor: 19.112

8.  Gemfibrozil, a Lipid-Lowering Drug, Lowers Amyloid Plaque Pathology and Enhances Memory in a Mouse Model of Alzheimer's Disease via Peroxisome Proliferator-Activated Receptor α.

Authors:  Sujyoti Chandra; Kalipada Pahan
Journal:  J Alzheimers Dis Rep       Date:  2019-05-18
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.